Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1989-09-19
1996-07-30
Wax, Robert A.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 2, 514 21, 530380, 530397, A61K 3816, A61K 3514, A01N 3718, C07K 100
Patent
active
055411584
ABSTRACT:
A method for increasing the hematocrit of a normal mammal using erythropoietin (EPO) is provided. The method comprises the steps of administering to the mammal a hematocrit increasing effective amount of EPO, in a pharmaceutically acceptable form. Additionally administered is an effective amount of iron, in a pharmaceutically acceptable form, sufficient to increase the serum iron content of the mammal to an erythropoiesis supportable level. The method is useful for increasing the amount of blood that can be donated for transfusion purposes, in particular autologous transfusion.
REFERENCES:
patent: 5013718 (1991-05-01), Adamson et al.
Hauer et al. (1984) Vox Sang. 46:8-12.
Udupa et al. (1984) J. Lab. Clin. Med. 103:574-580.
Egrie et al. (1985) Prog. Clin. Biol. Res. 191:339-350.
Rodgers et al. (1975) Proc. Soc. Exp. Biol. Med. 148:380-382.
Schustack et al. (1985) Clin. Nephrology 23(6):303-306.
Hedstrand et al. (1977) Scand. J. Haematol. 19:417-423.
Cottino et al. (1985) Acta Gerontol. 35(3/4):217-222 (abstract only).
Maeda et al. (1989, Jul. 29) The Lancet 2(8657):284.
Levine et al. (1988) Surgery 104:365-369.
Masunaga et al., Acta Haematol JPN, 49(4):807-815 (1986).
Essers et al., Proc. Eur. Dial. Transplant Assoc., 11:398-402 (1974).
Winearls et al., Lancet, pp. 1175-1178 (Nov. 22, 1986).
Eschbach et al., N. Eng. J. Med., 316:73-78 (1987).
Eschbach et al, J. Clin. Invest., 74:434-441 (1984).
Egrie et al., Immunobiol., 172:213-224 (1986).
Spivak et al., Johns Hopkins Med. J., 146:311-320 (1980).
Schustack et al., Clin. Nephrol., 23(6):303-306 (1985).
Estrella et al., Clinica Chimica Acta, 164:1-6 (1987).
Hedstrand et al., Scand. J. Haematol., 19(5):417-423 (1977).
Udupa et al., J. Lab. Clin. Med., 103(4):574-580 (1984).
Feleppa, Scand. J. Haemat., 10:186-188 (1973).
Feleppa, Pharm. Res. Comm., 4(4):363-367 (1972).
Beru et al., J. Biol. Chem., 260(16):9251-9257 (1985).
Rotruck et al., J. Agric. Food Chem., 27(1):27-33 (1979).
Kickler et al., JAMA, 260(1):65-67 (1988).
Levine et al., J. Trauma, 29(8):1134-1139 (1989).
Maeda et al., Lancet, p. 284 (Jul. 29, 1989).
Schwenk et al., DICP, 23(7-8):528-536 (1989).
Levine et al., Surgery, 104(2):365-369 (1988).
Goodman & Gilman's, The Pharmacological Basis of Therapeutics, 7th Ed., pp. 1131-1134 (1985).
Abels Robert I.
Anderson Freedolph D.
Harris William L.
Thompson Dorothy
Vance John F. A.
Hobbs Lisa J.
Ortho Pharmaceutical Corporation
Wallen III John W.
Wax Robert A.
LandOfFree
Method for increasing the hematocrit of a normal mammal does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for increasing the hematocrit of a normal mammal, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for increasing the hematocrit of a normal mammal will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1658589